Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
CLN-619 by Cullinan Therapeutics for Ovarian Cancer: Likelihood of Approval
CLN-619 is under clinical development by Cullinan Therapeutics and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase...
Data Insights
Risk adjusted net present value: What is the current valuation of Cullinan Therapeutics's CLN-619?
CLN-619 is a monoclonal antibody commercialized by Cullinan Therapeutics, with a leading Phase I program in Metastatic Transitional (Urothelial) Tract...